RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on blood pressure response |
|
Usual maintenance dose
|
12.5–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
| Parameter | Recommendation |
|
Starting dose
|
3.125 mg twice daily for 2 weeks (initiate only in euvolemic, stable CHF) |
|
Titration
|
Double dose every 2 weeks as tolerated |
|
Usual maintenance dose
|
25 mg twice daily (patients <85 kg); 50 mg twice daily (patients >85 kg) |
|
Maximum dose
|
25 mg twice daily (<85 kg); 50 mg twice daily (>85 kg) |
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on heart rate and symptom control |
|
Usual maintenance dose
|
12.5–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily (initiate 3–21 days post-MI when haemodynamically stable) |
|
Titration
|
Double dose every 3–10 days as tolerated |
|
Usual maintenance dose
|
25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
|
Duration
|
Long-term; in combination with ACE inhibitor and statin |
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase based on heart rate and blood pressure; aim for HR 55–60 bpm while maintaining systolic BP >90 mmHg |
|
Usual maintenance dose
|
6.25–12.5 mg twice daily |
|
Maximum dose
|
12.5 mg twice daily (limited by hypotension in cirrhosis) |
|
Duration
|
Long-term prophylaxis |
| Parameter | Recommendation |
|
Starting dose
|
3.125–6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on ventricular rate control |
|
Usual maintenance dose
|
6.25–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
|
Target
|
Resting heart rate <110 bpm (lenient) or <80 bpm (strict) |
| Parameter | Recommendation |
|
Starting dose
|
0.05 mg/kg/dose twice daily |
|
Titration
|
Increase every 1–2 weeks as tolerated; double dose at each step |
|
Usual maintenance dose
|
0.2–0.4 mg/kg/dose twice daily (0.4–0.8 mg/kg/day total) |
|
Maximum dose
|
0.5 mg/kg/dose twice daily (1 mg/kg/day total) |
|
Minimum age
|
Not recommended below 2 years except under paediatric cardiologist guidance |
| Renal Function | Recommendation |
| Mild to moderate impairment (CrCl >30 mL/min) | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; monitor closely for bradycardia and hypotension |
| Haemodialysis | Not significantly dialysed; no supplemental dose required |
| Severity | Recommendation |
| Mild impairment | Start cautiously at 3.125 mg twice daily; slower titration |
| Moderate impairment | Use lower starting doses (3.125 mg twice daily); titrate very slowly; monitor closely for hypotension |
| Severe impairment |
Avoid use — significantly increased drug exposure and risk of adverse effects; contraindicated in patients with clinically evident hepatic impairment
|
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed and benefits outweigh risks; crosses placenta |
| Risk | Fetal bradycardia, hypoglycaemia, intrauterine growth restriction, hypotension |
| Preferred alternatives | Labetalol (first choice for hypertension in pregnancy); methyldopa |
| When it may be used | Only under obstetric and cardiology specialist supervision if preferred alternatives not suitable |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose monitoring for 48–72 hours post-delivery |
| Consideration | Recommendation |
| Compatibility | Compatible with breastfeeding with caution |
| Drug levels in milk | Low (minimal transfer expected) |
| Preferred alternatives | Labetalol, propranolol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding difficulties, lethargy, poor weight gain, signs of beta-blockade |
| Consideration | Recommendation |
| Starting dose | 3.125 mg twice daily |
| Titration | Slower titration required — increase dose at 2–4 week intervals |
| Risks | Orthostatic hypotension, dizziness, bradycardia, falls, fatigue, cognitive effects |
| Monitoring | Standing blood pressure, heart rate, renal function |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; increased risk of severe bradycardia, AV block, heart failure |
Avoid combination or use with extreme caution; ECG monitoring required
|
| Amiodarone | Additive bradycardia and conduction abnormalities |
Use with caution; regular ECG and heart rate monitoring
|
| Digoxin | Carvedilol increases digoxin levels (by ~15%); additive bradycardia |
Monitor digoxin levels and heart rate; consider digoxin dose reduction
|
| CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) | Increased carvedilol plasma levels via inhibition of metabolism |
Monitor for excessive beta-blockade; consider dose reduction
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped abruptly |
Discontinue carvedilol several days before stopping clonidine; taper clonidine slowly
|
| Insulin and sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor) |
Monitor blood glucose closely; educate patient on hypoglycaemia signs
|
| MAOIs | Risk of severe hypertension |
Avoid combination
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Additive negative inotropic and conduction effects |
Avoid or use with extreme caution
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Rifampicin | May significantly reduce carvedilol efficacy via CYP induction | Monitor blood pressure and heart rate; may need dose adjustment |
| NSAIDs | May attenuate antihypertensive effect via prostaglandin inhibition and sodium retention | Monitor blood pressure |
| Cimetidine | May increase carvedilol levels | Monitor for excessive beta-blockade |
| Cyclosporine | Carvedilol may increase cyclosporine levels | Monitor cyclosporine levels |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist; do not discontinue abruptly before surgery |
| Tricyclic antidepressants | Additive orthostatic hypotension | Monitor blood pressure |
| Alpha-blockers (prazosin, doxazosin) | Additive hypotensive effect and orthostatic hypotension | Use with caution; consider dose reduction |
| Antidiabetic agents (other than insulin/sulfonylureas) | May alter glycaemic control | Monitor blood glucose |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Sildenafil and other PDE5 inhibitors | Additive hypotensive effect | Use with caution; monitor blood pressure |
| Adverse Effect | Clinical Note |
| Severe bradycardia or AV block | May require dose reduction, discontinuation, or temporary pacing; atropine may be needed |
| Worsening heart failure | May occur during initiation/up-titration; manage with diuretic adjustment; temporary dose reduction may be needed |
| Bronchospasm | Discontinue immediately if significant; more likely in patients with reactive airway disease |
| Severe hypotension / Syncope | Particularly with first dose or during up-titration; may require dose reduction |
| Hepatic dysfunction | Rare elevation in transaminases; discontinue if ALT/AST >3× ULN with symptoms |
| Stevens-Johnson Syndrome / Toxic epidermal necrolysis | Rare; discontinue immediately and seek emergency care |
| Acute renal failure | In severe heart failure with renal hypoperfusion |
| Phase | Parameters |
|
Baseline
|
Blood pressure (supine and standing), heart rate, ECG (if cardiac history), liver function tests, renal function, weight, blood glucose (in diabetics) |
|
During up-titration
|
Blood pressure and heart rate at each dose increase (weekly during titration); weight; signs and symptoms of worsening heart failure |
|
Long-term
|
Blood pressure, heart rate every visit; liver function tests every 6 months; periodic renal function; weight; symptoms of heart failure progression |
| Strength | Approximate Price Range (per tablet) |
| 3.125 mg | ₹1–₹2 |
| 6.25 mg | ₹2–₹4 |
| 12.5 mg | ₹3–₹6 |
| 25 mg | ₹5–₹10 |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.